New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David Radspinner and the securing of USD 64 million in funding led by Decheng Capital. The company, established by scientists Sun Junwei and Dr. Zhou Shangzhen, who were instrumental in the development of the first viral vectors, has also operationalized a custom-built manufacturing facility in Philadelphia.
Focus on High-Quality Viral Vectors for CGT
VintaBio is dedicated to developing and manufacturing consistent, high-quality viral vectors that are crucial for cell and gene therapy (CGT) development. The company aims to address the lack of manufacturing capacity related to viral vectors, which has been a significant industry bottleneck in recent years.
Founder and CEO Backgrounds
Sun Junwei is a co-founder of Spark Therapeutics, a University of Pennsylvania spinout that developed Luxturna (voretigene neparvovec), the first-ever FDA-approved gene therapy now marketed by Roche in the US and Novartis globally. Dr. Zhou Shangzhen also played a key role in creating Zolgensma (onasemnogene abeparvovec), the second FDA-approved gene therapy and a Novartis product for spinal muscular atrophy. CEO David Radspinner brings extensive experience from positions held at ILC Dover, Cytiva, GE Healthcare Life Sciences, and Thermo Fisher Scientific.-Fineline Info & Tech
